FDA Panel To Review Prestwick's Xenazine For Huntington's Chorea
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Peripheral and Central Nervous Systems Advisory Committee assesses the risk-benefit profile of tetrabenazine for the indication Dec. 7.